From the Journals

Cardiovascular risks vary by race/ethnicity in lupus patients

View on the News

Paradox? Maybe not

In the 1,000 Faces of Lupus study, which showed a comparable racial and ethnic paradox, “lower annual income was associated with more health care barriers” and “difficulty in obtaining medications was associated with higher disease activity,” Janet E. Pope, MD, and her associates said in an accompanying editorial.

“The observed ‘paradox’ from the Barbhaiya study may be the result of complex interactions between environmental, cultural, socioeconomic, psychosocial, genetic, and other clinical factors.

Dr. Janet E. Pope

Dr. Janet E. Pope

It is entirely possible that some of these factors may be working in opposite directions or [that] even the instruments used to collect data may have been derived from one ethnic source and not appropriate to use in another group,” they wrote (Arthritis Rheumatol. 2017. doi: 10.1002/art.40173).

Dr. Pope is with the University of Western Ontario in London. Her coauthors were Michael H. Weisman, MD, who is with Cedars-Sinai Medical Center in Los Angeles and Christopher Sjöwall, MD, of Linköping (Sweden) University.


 

FROM ARTHRITIS AND RHEUMATOLOGY

Black patients with systemic lupus erythematosus (SLE) are more likely than whites to have a cardiovascular event, but Hispanics, Asians, and American Indians/Alaska natives with SLE are less likely than whites to experience a CV event, according to a study involving almost 66,000 Medicaid patients.

In a comparison of incidence rate ratios with whites as the reference group (IRR, 1.0), black patients with SLE had an IRR of 1.18 for cardiovascular events (defined as a first acute myocardial infarction or stroke), Hispanic patients had an IRR of 0.84, Asians had an IRR of 0.75, and American Indians/Alaska natives had an IRR of 1.06, reported Medha Barbhaiya, MD, MPH, of Brigham and Women’s Hospital, Boston, and her associates (Arthritis Rheumatol. 2017. doi: 10.1002/art.40174).

MI + stroke incidence rate ratios for SLE patients, 2000-2010
The two components of the CV event rate did not always contribute equally, however. Blacks with SLE had a significantly higher risk of stroke, compared with whites, but the MI risk was almost equal. Hispanics also had a significantly higher stroke rate than did whites, but the MI risk for Hispanics was significantly lower. For Asian SLE patients, stroke and MI risks both were lower than for whites, but only the difference for MI was significant. The MI risk for American Indians/Alaska natives was lower, compared with whites, and the stroke risk was higher, but neither difference was significant, the investigators said.

The substantial reduction in MI risk among Hispanics and Asians, compared with white SLE patients, suggests an “Hispanic and Asian paradox” since “SLE has been reported to be more prevalent, more severe, and to result in more end-organ damage in Hispanics and Asians compared to white patients,” Dr. Barbhaiya and her associates wrote.

The data for 65,788 cases of SLE from Jan. 1, 2000, to Dec. 31, 2010, were taken from the Medicaid Analytic eXtract, which contains all Medicaid billing claims from the 29 most populous states. Over a mean follow-up of 3.8 years, those SLE patients had 2,259 first-CV events, which works out to an overall incidence rate of 9.31 per 1,000 person-years.

The study was supported by awards from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Dr. Barbhaiya and one of her associates are supported by awards from the Rheumatology Research Foundation. The investigators did not disclose any conflicts.

Recommended Reading

No increase in hand osteoarthritis seen in Sjögren’s syndrome
MDedge Rheumatology
New ACR-EULAR diagnostic criteria proposed for ANCA-associated vasculitides
MDedge Rheumatology
Cutaneous manifestations can signify severe systemic disease in ANCA-associated vasculitis
MDedge Rheumatology
SLE linked to subsequent risk of malignant melanoma
MDedge Rheumatology
CC-220 shows efficacy, safety concerns in phase II SLE trial
MDedge Rheumatology
Mepolizumab proves effective for eosinophilic granulomatosis with polyangiitis
MDedge Rheumatology
FDA approves first specific treatment for giant cell arteritis
MDedge Rheumatology
Study confirms new mutation, possible therapeutic target in epidermolysis bullosa
MDedge Rheumatology
EMEUNET tailors EULAR experience for young rheumatologists
MDedge Rheumatology
EULAR program features novel treatments and targets in immune pathways and key overviews of the field
MDedge Rheumatology